This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

Tesla (NASDAQ: TSLA) shares continued a recent slide, hitting a two-year low Monday. As of 2:25 p.m. ET, the stock was down 6.8% to about $168 per share. That’s the lowest level since November 2020. 

The reasons for today’s decline are some of the same that have contributed to the more than 40% drop in the stock over the last three months. But there are some new developments as well. 

So what

Investors have been shedding Tesla shares as CEO Elon Musk has had to sell some of his own this year to fund his Twitter acquisition. Musk has sold about $19 billion in total related to the Twitter purchase in 2022. He has also had to put his time and energy into the social media company recently. 

Today’s drop also can be attributed to a newly announced recall, as well as renewed concerns over COVID-19 restrictions in China. 

Now what

China announced three COVID-19 deaths in its capital, Beijing, over the weekend. That marked the first official fatalities attributed to the virus in China since May. As cases continue to increase, authorities also locked down the most populous portion of the large southern port city of Guangzhou. Tesla’s largest plant is in Shanghai, and investors fear an interruption in sales from that facility could have noticeable impacts on the company’s fourth quarter. 

It also didn’t help investor sentiment when a recall of 321,000 Tesla vehicles in the U.S. was announced over the weekend. That said, the news was more of a headline than a concern for impacts to the business, however. The recall was for a rear taillight issue that the company will fix with over-the-air updates.

But investors see several things piling on right now, and Tesla stock still holds a high valuation by traditional metrics. Its price-to-earnings (P/E) ratio remains above 50 on a trailing-12-month basis. So the recent news affecting the business and the brand is moving the stock lower and lower. For long-term investors, that could be an opportunity to begin dipping into the stock, as the business’ prospects continue to grow. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why Tesla shares hit a 2-year low today appeared first on The Motley Fool Australia.

(function() { function setButtonColorDefaults(param, property, defaultValue) { if( !param || !param.includes(‘#’)) { var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0]; button.style[property] = defaultValue; } } setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’); setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’); setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’); })()

More reading

• Why Tesla stock could have 930% upside: expert
• Ex-Tesla Australia boss faces 15 years’ jail for insider trading ASX lithium shares
• Here’s what drove Tesla shares back above $200 today
• Why is Tesla stock falling today?
• Why Tesla shares jumped today

Howard Smith has positions in Tesla. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Tesla. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/fXUdDrY

With so much interest in ASX lithium shares in recent years, many of the established producers seem to be fully priced.

The lithium price itself has roughly tripled this year, making many experts wary about whether the larger producers have had their run.

Arguably, in order to capture the best returns, investors may need to look at smaller players that haven’t yet fully realised their potential.

One of those is Global Lithium Resources Ltd (ASX: GL1).

The $497 million company is still at an exploratory stage, with a focus on the Marble Bar Lithium Project in Western Australia’s Pilbara region.

Last month, Global Lithium issued new shares to raise $100 million to fund a takeover of the Manna Lithium Project from Breaker Resources NL (ASX: BRB).

Shaw and Partners portfolio manager James Gerrish was asked recently whether he would consider buying this stock, considering the already-elevated lithium prices.

Medium-term prospects ‘very positive’

Gerrish told a Market Matters Q&A that he was still bullish on both the lithium thematic and Global Lithium shares.

But with a caveat.

“We are more cautious in the short-term because of market positioning,” he said.

“Hence a scaled-in approach is worth considering… around $2.30 adding to the position over time.”

The Global Lithium share price closed 1.25% higher on Monday at $2.43.

The stock has roughly doubled since the start of the year, and Gerrish can’t see any reason why that ascent can’t continue.

“The medium-term backdrop here is a very positive one in our view.”

Gerrish is not the only professional loving the look of Global Lithium shares at the moment.

According to CMC Markets, all four analysts currently covering the stock are rating it as a strong buy.

The analysts at Macquarie agree, according to Livewire, predicting a potential 90% upside for Global Lithium stocks at current lithium spot prices.

The post Could this ASX share be the next lithium stock to explode? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why is the Global Lithium share price tanking 9% today?
• Guess which ASX lithium share has just been halted amid a major acquisition and cap raise

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/BLHCpSN

If you’re looking for ASX dividend shares to buy, then you could do a lot worse than the two listed below.

Both of these ASX dividend shares have recently been named as buys. Here’s why experts say they could be worth considering:

Baby Bunting Group Ltd (ASX: BBN)

The first ASX dividend share for income investors to consider is leading baby products retailer Baby Bunting.

Analysts at Morgans remain positive on the company and currently have an add rating and $3.60 price target on its shares. While disappointed with its first quarter margins, the broker feels that its shares have been oversold. It said:

With the shares nearly 30% lower than they were before the AGM, there has, in our view, been an overreaction to the update. BBN is still the largest specialist in a comparatively defensive retail segment. It still has compelling opportunities to grow its share of a growing market through store rollout, entry into New Zealand, range expansion and the launch of an online marketplace. It’s trading on 12x FY24 P/E. ADD.

In respect to dividends, the broker is forecasting fully franked dividends per share of 14 cents in FY 2023 and then 16 cents in FY 2024. Based on the current Baby Bunting share price of $2.56, this will mean yields of 5.5% and 6.3%, respectively.

Healthco Healthcare and Wellness REIT (ASX: HCW)

Another ASX dividend share to look at is the Healthco Healthcare and Wellness REIT.

Goldman Sachs is a fan of this health and wellness focused real estate investment trust and has a conviction buy rating and $2.05 price target on its shares.

The broker likes the company due to its strong balance sheet, positive tenant mix, and the resilient valuations in the healthcare sector. It commented:

[T]he REIT remains one of our top picks in the sector given 1) its net cash position with over $450mn of liquidity, providing flexibility for near term opportunities, 2) its diversified mix of strong tenant covenants in sub-sectors that are majority government-backed across the care spectrum, mitigating potential tenant credit risks, 3) Healthcare and childcare assets valuations have remained resilient, 4) the expansive forecast future demand for assets across the care spectrum, underpinning development opportunities, and 5) inexpensive valuation.

As well as decent upside, Goldman is expecting attractive dividend yields from the Healthco Healthcare and Wellness REIT.

It has pencilled in dividends per share of 7.5 cents in both FY 2023 and FY 2024. Based on the current Healthco Healthcare and Wellness REIT unit price of $1.58, this will mean yields of 4.75% for income investors.

The post Experts say these ASX dividend shares are buys today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• 3 key things I look for when buying ASX dividend shares
• Buy these ASX dividend shares now: Goldman Sachs
• Why I think these ASX dividend shares can double in 7 years AND pay income along the way
• Analysts name 2 ASX dividend shares to buy right now
• Why Baby Bunting, James Hardie, Sims, and Temple & Webster shares are dropping

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Baby Bunting. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://www.fool.com.au/2022/11/22/experts-say-these-asx-dividend-shares-are-buys-today-2/

If you own technology stocks, you need not be reminded 2022 has been an annus horribilis.

The S&P/ASX All Technology Index (ASX: XTX) is now more than 30% lower than where it started the year, and many individual ASX shares have halved in value.

This industry-wide devaluation happened largely because of the fear of rising interest rates.

The technology sector is full of growth companies, which are valued on the basis of their future potential. Therefore when the cost of money rises, their prospects decline.

But now, with just six weeks left in the year, relief is in sight.

Although the Reserve Bank is still in the middle of hiking rates, the market is starting to look forward to this part of the cycle slowing or even ceasing altogether.

Therefore many experts, such as Shaw and Partners portfolio manager James Gerrish, are tipping a resurgence for ASX tech shares heading into Christmas.

“The underlying theme is we’re looking for a recovery in the tech sector.”

But which tech stocks are the best ways to take advantage?

Best large-cap tech stock

Gerrish this week said that there’s no doubt not all tech stocks are built the same, and we would see a big variation in performance between individual shares.

“At this stage, we would pick out three for very different reasons depending on an investor’s goal/risk appetite,” he told a Market Matters Q&A.

Out of the large caps, Gerrish’s team favours Altium Limited (ASX: ALU).

The stock closed Monday at $36.27.

“We believe this is a top quality ASX tech name which looks destined to break well above $40 into 2023,” said Gerrish.

“This would be a number one large-cap tech pick.”

The electronics design software maker has proven relatively resilient, only losing 16.2% year to date. In fact, the Altium share price has risen almost 50% since the middle of June.

Best high risk-reward play

For a higher risk but potentially higher reward play, Gerrish likes New Zealand software provider Xero Limited (ASX: XRO).

“After falling 60% in 2022, this online accounting [stock] could squeeze sharply into 2023,” he said.

“At this stage, it’s more of an aggressive play than Altium, in our opinion.”

Despite the disastrous plunge in share price this year, Xero shares have still gained 131% for investors over the past five years.

How about the best tech in the world?

Of course, the ASX is far from claiming to be the home of technology. The best and brightest in that sector list is on the NASDAQ in the United States.

For this reason, Gerrish’s third pick is Betashares Nasdaq 100 ETF (ASX: NDQ).

Even though it’s an index exchange-traded fund (ETF), he expects serious returns over the next few weeks.

“We hold this ASX traded ETF in our Macro ETF Portfolio,” said Gerrish.

“We can see it rallying 10% to 15% into Christmas.”

The Betashares Nasdaq 100 ETF share price has dipped more than 26% year to date.

The post 3 ASX shares to buy for the end-of-year tech comeback: expert appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why did the Altium share price sink into the red today?
• 5 things to watch on the ASX 200 on Monday
• 3 top ETFs for ASX investors to buy and hold for a decade
• I’d use the Warren Buffett method to create a ‘best ASX shares to buy now’ list
• 3 key things I look for when buying ASX dividend shares

Motley Fool contributor Tony Yoo has positions in BETANASDAQ ETF UNITS and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Altium, BETANASDAQ ETF UNITS, and Xero. The Motley Fool Australia has positions in and has recommended BETANASDAQ ETF UNITS and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://www.fool.com.au/2022/11/22/3-asx-shares-to-buy-for-the-end-of-year-tech-comeback-expert/

Ask a Fund Manager

The Motley Fool chats with fund managers so that you can get an insight into how the professionals think. In part two of this edition, we’re rejoined by Andrew Martin, principal of Alphinity Investment Management. The Alphinity Concentrated Australian Share Fund has delivered an annual return of 7.6% after fees over the past five years.

The Motley Fool: In part one of our interview yesterday we talked about some of your best calls in 2022. Do you have any regrets over the past year, things that with 20:20 hindsight you wish you had or maybe had not done in the investment markets?

Andrew Martin: We had some exposure to lithium through IGO Ltd (ASX: IGO). But in hindsight, I wish we had more exposure to lithium stocks. Our exposure has done incredibly well. And some of these stocks are so large now that if you don’t have a position it can really hurt you. Where they go from now, is another question.

The other one would be, in hindsight, exposure to rising interest rates. I always thought they were going up, but they have gone up much faster and harder than the market expected.

So, a company like Computershare Limited (ASX: CPU), which has got real exposure to rising short-term rates, has done very well. We don’t own that one. We find it a bit risky when it’s just picking macro things like rates going up, we prefer it to be more operational focused. But with hindsight, we’d potentially take a position in something like that, given the exposure it gets to rising rates.

MF: You still hold IGO shares today. What’s your outlook for this ASX 200 lithium stock?

AM: Lithium, as a commodity, is still doing very well. One of the reasons we were there is the markets were taking time to catch up with that story, as in what they expect the lithium price to be going forward.

It always tempers things a little bit when they’ve done so well. We can’t have the same conviction we had six months ago, given how well they’ve all done.

The outlook for lithium is still positive, and hence we still have an exposure.

But, like everything, we don’t want to buy companies just because they have exposure to lithium. We want more to the story. We like IGO as a business and their strategy.

MF: When we spoke back in September 2021, you stressed the importance of earnings and investing in quality, undervalued companies in an earnings upgrade cycle. Which ASX 200 shares fit that bill today?

AM: In this kind of market there are always those kinds of companies.

Qantas Airways Limited (ASX: QAN) is one of those. We’ve seen some really good earnings upgrades come through.

People have been grumbling about them, lost bags and delays and what have you. But the reality is that pricing is going up, there’s very strong demand domestically and offshore. And there’s just not a lot of capacity around. So they are able to generate very good profits, and very good cash flow which rapidly improves the quality of the balance sheet.

I think the ASX 200 banks are sitting in this space as well. In this reporting season, we’re still seeing earnings upgrades for the banks. They have very strong balance sheets at the moment; great capital; great provisioning positions.

We prefer National Australia Bank Ltd (ASX: NAB) and Commonwealth Bank of Australia (ASX: CBA). They are not the cheapest banks, but we think from a performance perspective they are doing better than the other banks.

And another one is Steadfast Group Ltd (ASX: SDF), an insurance broking business.

They’re in a great market environment at the moment, where insurance premiums are going up. And they can be taking a commission and fee off the back of that. They’re also buying up small stakes in broking businesses and building out their network. And they’re in a very consistent upgrade cycle. It’s a very strong quality business with a very strong quality management team as well.

**

Tune in tomorrow for part three of our interview with Andrew Martin. If you missed part one, just click here.

(You can find out more about Alphinity’s Australian, Global, and Sustainable funds here.)

The post 4 quality, undervalued ASX 200 shares in an earnings upgrade cycle revealed: fund manager appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Are ASX 200 bank shares a buying opportunity hiding in plain sight?
• Why this fund manager sees tailwinds ahead for the Qantas share price
• 3 reasons why I think it’s time to snap up NAB shares
• Why these 3 ASX 200 shares have done ‘particularly well’ and remain top holdings into 2023: fund manager
• Here’s the CBA dividend forecast through to 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Steadfast Group Ltd. The Motley Fool Australia has positions in and has recommended Steadfast Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/aJeyPHX

The Core Lithium Ltd (ASX: CXO) share price enjoyed its first gains on Monday in five trading days.

The S&P/ASX 200 Index (ASX: XJO) lithium stock finished 0.4% higher yesterday at $1.41 per share on no fresh price-sensitive news. But that still leaves Core Lithium down 25% since last Monday’s closing bell, when it closed at $1.87.

So, what’s going on?

What are ASX 200 investors considering?

The Core Lithium share price has been on quite a rollercoaster over the past six trading days.

A week ago on Monday, the lithium miner gained 11.7%, only to plummet 15.8% on Tuesday. And shares finished well into the red for the remainder of the week.

Core Lithium has been riding high on the back of booming lithium demand. The battery critical metal remains near record prices as global EV production continues to ramp up.

And much of that demand comes from China, a world leader in EV manufacturing.

Which brings us back to the big surge and subsequent fall in the Core Lithium share price.

Last Monday (14 November) it looked like China was ready to significantly ease its economy crippling COVID zero policies. Any such easing of the rolling lockdowns would spell good news for China’s economy along with its voracious appetite for lithium.

But just a day later, news emerged of surging COVID cases in the Middle Kingdom, dampening investor enthusiasm for Core Lithium and indeed most lithium shares as 2023 could now potentially see supplies catch up to demand.

You’re unlikely to hear too much whinging from investors who bought shares last year though. Despite the big fall over the past week, the lithium miner remains up 147% over 12 months.

How has the Core Lithium share price performed longer-term?

That’s a smashing 12-month gain by Core Lithium.

But as investors with a truly longer-term horizon, we like to look at the five-year returns. And over the past five years, the Core Lithium share price has rocketed an eye-popping 1,777%.

The post The Core Lithium share price has tanked 25% in a week. What’s going on? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the 3 most heavily traded ASX 200 shares on Monday
• Why is the Lake Resources share price smashing the ASX 200 on Monday?
• Core Lithium share price leaps higher for first time in 5 trading sessions
• Ballin’ on a budget: The best ASX shares to buy for under $5
• Did the Core Lithium chair really just offload $1 million of his shares?

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/HLdsnaT

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small decline. The benchmark index fell 0.2% to 7,139.3 points.

Will the market be able to bounce back from this on Tuesday? Here are five things to watch:

ASX 200 expected to rise

The Australian share market looks set to rebound on Tuesday. This is despite relatively a poor start to the week on Wall Street. According to the latest SPI futures, the ASX 200 is poised to open the day 33 points or 0.45% higher. In late trade in the United States, the Dow Jones is flat, the S&P 500 is down 0.3%, and the NASDAQ has tumbled 1%.

Pro Medicus shares downgraded

The Pro Medicus Limited (ASX: PME) share price could be fully valued according to analysts at Morgans. According to a note, the broker has downgraded the health imaging company’s shares to a hold rating with a $58.18 price target. This is broadly in line with where its shares trade today. Morgans commented: “PME is expensive for a reason but given the recent rally in the share price running through our target price, we pare our recommendation back to Hold.”

Oil prices fall

Energy producers such as Beach Energy Ltd (ASX: BPT) and Santos Ltd (ASX: STO) could have a subdued day after oil prices dropped overnight. According to Bloomberg, the WTI crude oil price is down 0.7% to US$79.50 a barrel and the Brent crude oil price has fallen 0.4% to US$87.27 a barrel. Concerns over Chinese demand weighed on prices.

Annual general meetings

There are a large number of ASX 200 companies holding their annual general meetings today. These companies could provide the market with trading updates at their respective events. Among the shares holding events are steel manufacturer BlueScope Steel Limited (ASX: BSL), building products company Brickworks Limited (ASX: BKW), iron ore miner Fortescue Metals Group Limited (ASX: FMG), and casino and resorts operator Star Entertainment Group Ltd (ASX: SGR).

Gold price drops

Gold shares Evolution Mining Ltd (ASX: EVN) and Regis Resources Limited (ASX: RRL) could have a poor day after the gold price traded lower overnight. According to CNBC, the spot gold price is down 0.8% to US$1,739.9 an ounce. That followed a strong bounce by the US dollar.

The post 5 things to watch on the ASX 200 on Tuesday appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why did the Mesoblast share price soar 9% today?
• Here are the top 10 ASX 200 shares today
• Why Fortescue, Healius, Nanosonics, and PEXA shares are dropping
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Why is the Rio Tinto share price trailing the ASX 200 on Monday?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Brickworks and Pro Medicus Ltd. The Motley Fool Australia has positions in and has recommended Brickworks and Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/f0iO1hT

Looking for dividend shares to buy? Listed below are two ASX dividend shares that analysts rate as buys.

Here’s why they are bullish on these dividend shares:

Adairs Ltd (ASX: ADH)

The first ASX dividend share to look at is this furniture and homewares retailer.

Its shares have been hammered this year and have lost over 40% of their value. While this is disappointing, Goldman Sachs believes it has created a buying opportunity and has put a buy rating and $2.65 price target on the company’s shares.

Its analysts believe the market is being too negative on Adairs’ outlook. It notes that “the market is pricing in EBIT that is 11-21% below the guidance range, and 12% below GSe.” It also highlights that it views “the core Adairs business as resilient in the current environment and do not believe the c.40% discount to discretionary retail peers is justified.”

Goldman is forecasting fully franked dividends per share of 17 cents in FY 2023 and 20 cents in FY 2024. Based on the latest Adairs share price of $2.22, this will mean yields of 7.7% and 9%, respectively.

Rural Funds Group (ASX: RFF)

Another ASX dividend share to consider is this Australian agricultural property company.

Its shares have also taken a tumble in 2022, which has caught the eye of analysts at Bell Potter.

The broker recently upgraded Rural Funds’ shares to a buy rating with a $2.75 price target on the belief that this share price weakness has created a buying opportunity. Bell Potter notes that “the current discount to adjusted NAV reflects what historically would be considered an attractive entry point.”

In addition, the broker is expecting Rural Funds’ dividend to continue growing in the coming years.

It is forecasting an 11.7 cents per share dividend in FY 2023 and then a 12.7 cents per share dividend in FY 2024. Based on the current Rural Funds share price of $2.57, this represents yields of 4.55% and 5%, respectively.

The post These growing ASX dividend shares are buy: analysts appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Ballin’ on a budget: The best ASX shares to buy for under $5
• 3 key things I look for when buying ASX dividend shares
• How I’d invest in ASX dividend shares now to make a $50k passive income in retirement
• Amidst the ongoing tech stock wreck, value shares are everywhere. There’s just one catch…
• Could ASX 200 retail shares be ‘too cheap’ to ignore right now? Here’s Scott Phillips’ take

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ADAIRS FPO. The Motley Fool Australia has positions in and has recommended ADAIRS FPO and RURALFUNDS STAPLED. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/9PDyjAG

The Imugene Limited (ASX: IMU) share price has had a tough run lately.

Imugene shares have dropped nearly 12% since market close on 15 November. The company’s share price was flat today and closed the day trading at 19 cents.

Let’s take a look at what is happening at Imugene.

What’s going on?

Imugene is a biotechnology company working on immunotherapies to treat cancer.

The Imugene share price descended nearly 10% last Wednesday,1 6 November. The S&P/ASX 200 Health Care Index (ASX: XHJ) also lost 1% on this day.

The dramatic fall on Wednesday followed the company’s share price soaring 5% on Tuesday, 15 November.

Imugene provided an investor presentation to the market on this day. The company highlighted it had $163.8 million in cash as of 30 September. The company has five unique assets, three platform technologies, 2 supply agreements, three scientific collaborations and 10 clinical studies.

On 17 November, Imugene held its AGM. The company’s share price was flat on this day. All resolutions at the meeting were carried but the company noted more than 25% voted against the 2022 remuneration report.

Highlights in 2022 included positive overall survival results in phase two of the HER-Vaxx trial, a clinical trial agreement with Roche to investigate the PD-1-Vaxx in combination with Tecentriq and cohort three cleared in the phase one study of CHECKvacc for treatment of patients with triple negative breast cancer. In the Vaxinia trial, the first patients were dosed and cleared in IV cohort 1 and IT cohort 2.

On 11 November, Imugene advised it has escalated the dose in the phase one clinical trial of Vaxinia. This treatment has been shown to shrink cancer tumours in animal models.

Imugene share price snapshot

The Imugene share price has tumbled 65% in the past year, while it has fallen 57% year to date.

For perspective, the ASX 200 has fallen nearly 3% in the last year.

Imugene has a market capitalisation of $1.14 billion based on the current share price.

The post Why has the Imugene share price tumbled 12% in under a week? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Monica O’Shea has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/IZPRDXB

The Mesoblast limited (ASX: MSB) share price took flight on Monday, soaring 9% to an intraday high of $1.02 before losing some ground in afternoon trading.

Shares in the ASX biotech company closed at 99 cents apiece today, up 6.45% from 93 cents at the market open.

The overall healthcare sector kicked off the week well, too, with the S&P/ASX 200 Health Care Index (ASX: XHJ) gaining 0.48%.

On a broader scale, the S&P/ASX 200 Index (ASX: XJO) petered out after a healthy start this morning to finish an unremarkable 0.17% lower.

Let’s take a look at what may have influenced the Mesoblast share price on Monday.

What happened?

There’s no news to report from Mesoblast today, and in fact, an absence of noteworthy announcements from the company for some time.

Our Fool writers last wrote about Mesoblast at the start of this month when we covered the company’s quarterly activities and cashflow report.

However, there are a couple of reasons that could help explain why Mesoblast’s shares have jumped higher. For one, the report noted that the company expected to receive FDA clearance to trial rexlemestrocel-L as a treatment for chronic back pain near the end of this year.

Rexlemestrocel-L and Remestemcel-L are the company’s mesenchymal precursor cell (MPC) products that Mesoblast is developing to treat various diseases.

Another possible share price driver today is that its annual general meeting (AGM) is approaching fast. Mesoblast will hold its AGM on Wednesday this week in Melbourne.

Some measures shareholders will vote on include the election and re-election of company directors and ratifying the issue of fully paid ordinary shares to major shareholders.

Mesoblast share price snapshot

The Mesoblast share price is down 29.29% year to date and a hefty 42% over the past 12 months. In comparison, the S&P/ASX 200 Index is down a respective 5.9% and 2.9% across the same time periods.

The company’s market capitalisation is around $729.7 million.

The post Why did the Mesoblast share price soar 9% today? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Here are the top 10 ASX 200 shares today
• Here are the 3 most heavily traded ASX 200 shares on Monday
• Why is the Rio Tinto share price trailing the ASX 200 on Monday?
• Why is the Lake Resources share price smashing the ASX 200 on Monday?
• 3 ASX 200 shares that hiked their dividends by more than 100% this year

Motley Fool contributor Matthew Farley has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/yqdQwjP